TheraCryf PLC

As of September 30, 2025, TheraCryf PLC carries a market capitalization of 462.03M, placing it among publicly traded companies globally. Its enterprise value stands at 112.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

TheraCryf PLC's next confirmed earnings release is scheduled for December 17, 2026.

As of September 30, 2025, TheraCryf PLC has 2.15B shares outstanding.

These figures are as of September 30, 2025.

As of September 30, 2025, TheraCryf PLC maintains a current ratio of 2.29, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended September 30, 2025.

As of the close on October 22, 2026, TheraCryf PLC's stock has declined approximately 16.67% over the past 52 weeks. The 50-day moving average sits at 0.18, while the 200-day moving average is 0.21.

These figures are as of September 30, 2025. Total book value stands at 480.20M, with working capital of 234.60M providing operational flexibility.

TheraCryf PLC's most recent stock split took place on February 12, 2021.